This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Santarus Reports Third Quarter 2013 Financial Results

Stocks in this article: SNTS

Santarus, Inc. (NASDAQ: SNTS) today reported financial and operating results for the quarter and nine months ended September 30, 2013. Key financial results include:

  • Total revenues of $98.8 million grew 81% compared with $54.7 million for the third quarter of 2012
  • Net income of $30.3 million, or $0.38 diluted earnings per share (EPS), compared with $9.0 million, or $0.13 diluted EPS for the third quarter of 2012
  • Non-GAAP adjusted earnings were $35.6 million and diluted non-GAAP adjusted EPS were $0.45 in the third quarter of 2013 compared with non-GAAP adjusted earnings of $12.3 million and diluted non-GAAP adjusted EPS of $0.18 for the third quarter of 2012
  • Cash, cash equivalents and short-term investments were $168.7 million as of September 30, 2013, an increase of approximately $74.0 million compared with $94.7 million at December 31, 2012

Santarus Conference Call Cancelled

The previously scheduled Santarus investor conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) today, November 7, 2013 has been cancelled as a result of the joint press release issued today after market close by Santarus and Salix Pharmaceuticals, Ltd. announcing that their Boards of Directors have unanimously approved a definitive merger agreement under which Salix will acquire Santarus through a tender offer followed by a merger for $32.00 in cash for a purchase price of approximately $2.6 billion.

Salix will host a conference call at 4:30 p.m. Eastern Time today, Thursday, November 7, 2013. Interested parties can access the conference call by way of webcast or telephone. The live webcast will be available at A replay of the webcast will be available at the same location. The telephone numbers to access the live conference call are (800) 319-9003 (U.S. and Canada) or (719) 325-2134 (international). The telephone numbers to access the replay of the call are (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international). The access code for the call is 612126.

Third Quarter 2013 Financial Results

Total revenues increased to $98.8 million for the third quarter of 2013, compared with $54.7 million for the third quarter of 2012 as indicated below ($ in millions):

  Three Months Ended   Increase
September 30, (Decrease)
  2013     2012
Product sales, net
GLUMETZA $ 45.6 $ 39.3 $ 6.3
ZEGERID 27.1 8.4 18.7
UCERIS 19.6 - 19.6
CYCLOSET 4.2 4.3 (0.1 )
FENOGLIDE   1.6   1.7   (0.1 )
Total product sales, net 98.1 53.7 44.4
Other revenue   0.7   1.0   (0.3 )
Total revenues $ 98.8 $ 54.7 $ 44.1

Net income for the third quarter of 2013 was $30.3 million and diluted EPS was $0.38. Non-GAAP adjusted earnings for the third quarter of 2013 were $35.6 million and diluted non-GAAP adjusted EPS were $0.45. In the third quarter of 2012 the company reported net income of $9.0 million, diluted EPS of $0.13 and non-GAAP adjusted earnings of $12.3 million, and had diluted non-GAAP adjusted EPS of $0.18.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs